Literature DB >> 28961571

Screening for Hepatopulmonary Syndrome in Cirrhotic Patients Using Technetium 99m-macroaggregated Albumin Perfusion Lung Scan (Tc-MAA): Diagnostic Approach and Clinical Correlations.

Maria Fragaki1, Dimitra Sifaki-Pistolla2, Dimitrios N Samonakis1, Mairi Koulentaki1, Sofia Koukouraki3, Maria Stathaki3, Elias Kouroumalis1.   

Abstract

BACKGROUND AND AIMS: The aims of this study were to prospectively screen cirrhotic patients with arterial blood gas test and albumin perfusion scan, identify those fulfilling the classic hepatopulmonary syndrome (HPS) criteria, correlate with clinical parameters, and evaluate the survival of patients with HPS compared with those without HPS in a genetically homogenous Cretan cirrhotic population.
MATERIALS AND METHODS: Data on consecutive 102 patients within 1 year were collected and analyzed. All patients underwent a technetium 99m-macroaggregated albumin perfusion lung scan (Tc-MAA). Diagnosis of HPS was based on the presence of the quantitative index Tc-MAA≥6% and a [P(A-a)O2]≥15 mm Hg (≥20 mm Hg for patients over >64 y).
RESULTS: In 94/102 patients, complete scintigraphic data were available. In total, 24 (26%) patients fulfilled the diagnostic criteria of HPS; 95.8% of them had mild-to-moderate HPS. In 8 patients the Tc-MAA scintigraphy could not be interpreted. There was no difference in HPS between decompensated (24.6%) and compensated cirrhosis (27.3%). In the multivariate analysis only the quantitative index was significant for the diagnosis of HPS (P=0.001, odds ratio; 95% confidence interval, 7.05; 2.27-21.87). Kaplan- Meier survival curves indicated a similar overall prognosis for patients diagnosed with HPS (P=0.105).
CONCLUSIONS: HPS is a frequent complication of cirrhosis. Mild-to-moderate HPS has no significant effect on survival of cirrhotic patients. The quantitative Tc-MAA test is a reliable tool for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28961571     DOI: 10.1097/MCG.0000000000000926

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

2.  Case Report: Hepatopulmonary syndrome as the first clinical manifestation of cirrhosis in a patient with underlying chronic lung disease.

Authors:  Charles Murphy; Danit Arad
Journal:  F1000Res       Date:  2018-08-02

3.  High-Dose Oral Garlic is Associated with a Decrease in Intrapulmonary Shunting in Severe Hepatopulmonary Syndrome.

Authors:  Tess McClure; Marcus Robertson
Journal:  Hepatol Commun       Date:  2019-09-23

4.  Hepatopulmonary Syndrome with Right-to-left Shunt in Cirrhotic Patients Using Macro-Aggregated Albumin Lung Perfusion Scan: Comparison with Contrast Echocardiography and Association with Clinical Data

Authors:  Zeynab Alipour; Abbas Armin; Sudabeh Mohamadi; Seyed Masoud Tabib; Zahra Azizmohammadi; Ali Gholamrezanezhad; Majid Assadi
Journal:  Mol Imaging Radionucl Ther       Date:  2020-02-17

Review 5.  Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives.

Authors:  Yannis Dimitroglou; Constantina Aggeli; Alexandra Alexopoulou; Sophie Mavrogeni; Dimitris Tousoulis
Journal:  J Clin Med       Date:  2019-12-03       Impact factor: 4.241

Review 6.  Pulmonary manifestations of chronic liver disease: a comprehensive review.

Authors:  Stergios Soulaidopoulos; Ioannis Goulis; Evangelos Cholongitas
Journal:  Ann Gastroenterol       Date:  2020-03-27

7.  Clinical outcomes and risk factors of hepatopulmonary syndrome in children.

Authors:  Kwang Yeon Kim; Tae Hyeong Kim; Jeong-Moo Lee; Nam-Joon Yi; Hyun-Young Kim; Jin Soo Moon; Jae Sung Ko
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 8.  Advances in Diagnostic Imaging of Hepatopulmonary Syndrome.

Authors:  Bi-Wei Luo; Zhi-Yong Du
Journal:  Front Med (Lausanne)       Date:  2022-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.